Skip to content

Vor Biopharma VOR Total Current Liabilities

Total Current Liabilities at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$57.72B+1.4%
Amgen logo
AmgenAMGN
$24.96B+8.5%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$3.88B+2.6%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$38.28M+126%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$35.15M+28.5%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$10.19M+23.7%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's total current liabilities?
Vor Biopharma (VOR) reported total current liabilities of $16.08M in Q1 2026.
How has Vor Biopharma's total current liabilities changed year-over-year?
Vor Biopharma's total current liabilities decreased by 3.9% year-over-year, from $16.73M to $16.08M.
What is the long-term trend for Vor Biopharma's total current liabilities?
Over 5 years (2020 to 2025), Vor Biopharma's total current liabilities has grown at a 19.8% compound annual growth rate (CAGR), from $10.21M to $25.17M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.